Education
About Us
Working with TipRanks
Follow Us
Cerus Corporation (CERS)
:CERS
CERS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $2.54
Previous CloseN/A
Volume302.69K
Average Volume (3M)1.53M
Market Cap
$247.10M
Enterprise Value$304.43M
Total Cash (Recent Filing)$18.99M
Total Debt (Recent Filing)$4.46M
Price to Earnings (P/E)―
Beta2.67
Next Earnings
May 01, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding185,789,810
10 Day Avg. Volume1,558,651
30 Day Avg. Volume1,528,061
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.58
Price to Cash Flow (P/CF)14.40
P/FCF Ratio18.00
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda-30.37
Forecast
1Y Price Target
$4.50Price Target Upside246.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Cerus News
PremiumCompany Announcements
Cerus Corporation’s 2024 Earnings Call Highlights Growth and Expansion
PremiumCompany Announcements
Cerus Corporation Reports Strong 2024 Financial Growth
PremiumCompany Announcements
Cerus Director Gail Schulze to Step Down---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCerus Corporation reported a Q4 top line beat and drove 15% year-over-year product revenue growth in 2024, surpassing its initial guidance.
ProfitabilityCERS delivered positive adjusted EBITDA of $5.7M for the full year, indicating a productive quarter from a profitability standpoint.
Bears Say
Regulatory ChallengesThe CE mark review for INTERCEPT RBCs in Europe concluded without an approval, marking a disappointing setback for the company.
Regulatory SubmissionThe review of CERS's CE Mark application for INTERCEPT RBC was completed without receiving approval, prompting the company to assess new strategies for regulatory submission.
---
Ownership Overview
15.71% Insiders
14.75% Mutual Funds
0.75% Other Institutional Investors
47.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CERS FAQ
What was Cerus Corporation’s price range in the past 12 months?
Cerus Corporation lowest stock price was $1.12 and its highest was $2.54 in the past 12 months.
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is $247.10M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is May 01, 2025 which is in 13 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Feb 20, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.012 by $0.002.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is -0.04.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 185,789,810 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went down -5.172%.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in CERS
---
Cerus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (246.15% Upside)
$4.50 (246.15% Upside)
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $94.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.61%
12-Months-Change
Fundamentals
Return on Equity
-38.45%
Trailing 12-Months
Asset Growth
1.60%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
---
CERS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Cerus Corporation's strong financial performance in 2024, marked by positive adjusted EBITDA and robust revenue growth driven by the IFC and global platelet businesses. However, challenges such as a decline in government contract revenue and increased operating expenses were noted. The overall sentiment is positive given the company's growth trajectory and market expansion efforts.Read More>---
CERS Stock 12 Month Forecast
Average Price Target
$4.50
▲(246.15% Upside)
Technical Analysis
Best Analysts Covering CERS
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-13.63%
reiterated a buy rating 2 months ago
Copying Josh Jennings's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -13.63% per trade.
---